Blood thinner dosing study for people with cancer starting treatment
Treatments studied
Part of Cancer, Heart & circulation clinical trials.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have an active solid tumor or lymphoma.
- You are starting a new cancer treatment or changing your current one.
- You have a calculated risk score of 2 for blood clots.
- You are not already on a blood thinner for treatment.
- You are not at high risk for bleeding (e.g., recent major surgery or brain tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a lower dose of the blood thinner apixaban (Eliquis) can safely prevent another blood clot in people with cancer who have a catheter-related clot in their upper arm or neck. It aims to find a balance between preventing clots and reducing bleeding risk.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
This trial studies the safety of managing blood thinners (like apixaban or warfarin) around the time of cancer surgery or procedures. It aims to help doctors understand how to best handle these medications to reduce risks.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This trial tests if apixaban, a blood thinner pill, can prevent dangerous blood clots in people with advanced lung cancer who are receiving outpatient chemotherapy or other systemic treatments. It aims to reduce the risk of venous thromboembolism (blood clots in veins) during cancer therapy.
This trial tests a new anticoagulant medication to treat and prevent blood clots in patients with active cancer. You may qualify if you have a recent clot in your leg or lungs and are already taking a blood thinner.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.